Hypertension and cardiovascular complications of chronic renal failure
Authors:
M. Souček 1; V. Monhart 2; M. Nedbálková 1
Authors‘ workplace:
II. interní klinika Lékařské fakulty MU a FN u sv. Anny v Brně, přednosta prof. MUDr. Miroslav Souček, CSc.
1; Interní klinika 1. lékařské fakulty UK a ÚVN Praha, přednosta prof. MUDr. Miroslav Zavoral, Ph. D.
2
Published in:
Vnitř Lék 2011; 57(7&8): 615-619
Category:
136th internal medicine day, XXIV. Vanýskův den, Brno 2011
Overview
Chronic renal failure is associated with a significant cardiovascular risk due to an increased incidence of cardiovascular risk factors (hypertension, diabetes mellitus, dyslipidemia). Cardiovascular mortality is due to an increased incidence of left ventricular hypertrophy, ischemic heart disease and chronic heart failure. Management focuses on risk factors, mainly high blood pressure in patients with mild to moderate chronic kidney disease, but it often fails in patients with chronic kidney failure.
Key words:
chronic renal failure – cardiovascular complications – arterial hypertension – antihypertensive agents
Sources
1. Tesař V. Kardiovaskulární rizikové faktory u chronického selhání ledvin. Kardiol Rev 2009; 11: 111–116.
2. Foley RN, Parfrey PS, Sarnak MJ. Clinical epidemiology of cardiovascular disease in chronic renal disease. Am J Kidney Dis 1998; 32 (5 Suppl 3): S112–S119.
3. Levey AS, Beto JA, Coronado BE et al. Controling the epidemic of cardiovascular disease in chronic renal disease: What do we know? What do we need to learn? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998; 32: 853–906.
4. National Kidney Foundation. K/DOQI clinical practice quidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (Suppl 2): S1–S266.
5. Levin A, Thompson CR, Ethier J et al. Left ventricular mass index increase in early renal disease: impact of decline in hemoglobin. Am J Kidney Dis 1999; 34: 125–134.
6. Moran A, Katz R, Jenny NS et al. Left ventricular hyperthrophy in mild and moderate reduction in kidney function determined using cardiac magnetic resonance imaging and cystatin C: the multi-ethnic study of atherosclerosis (MESA). Am J Kidney Dis 2008; 52: 839–845.
7. Levin A, Singer J, Thompson CR et al. Prevalent left ventricular hypertrophy in the predialysis population: identifying oportunities for intervention. Am J Kidney Dis 1996; 27: 347–353.
8. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606–1611.
9. Parfrey PS, Harnett JD, Foley RN et al. Impact of renal transplantation on uremic cardiomyopathy. Transplantation 1995; 60: 908–914.
10. Shlipak MG, Fried LF, Cushman M et al. Cardiovascular mortality risk in chronic kidney disease: comparison of traditional and novel risk factors. JAMA 2005; 293: 1737–1743.
11. Foley RN, Parfrey PS, Kent GM et al. Long-term evolution of cardiomyopathy in dialysis patients. Kidney Int 1998; 54: 1720–1725.
12. Foley RN, Parfrey PS, Harnett JD et al. The prognostic importance of left ventricular geometry in uremic cardiomyopathy. J Am Soc Nephrol 1995; 5: 2024–2031.
13. Foley RN, Parfrey PS, Morgan J et al. Effect of hemoglobin levels in hemodialysis patients with asymptomatic cardiomyopathy. Kidney Int 2000; 58:1325–1335.
14. Goldsmith D, Covic A. Coronary artery disease in uremia: etiology, diagnosis, and therapy. Kidney Int 2001; 60: 2059–2078.
15. Manske CL, Thomas W, Wang Y et al. Screening diabetic transplant candidates for coronary artery disease: identification a low risk subgroup. Kidney Int 1993; 44: 617–621.
16. Koch M, Gradus F, Schoebel FC et al. Relevance of conventional cardiovascular risk factors for the prediction of coronary artery disease in diabetic patients on renal replacement therapy. Nephrol Dia Transplant 2001; 16: 1198–1202.
17. Parfrey PS, Foley RN, Harnett JD et al. Outcome and risk factors of ischemic heart disease in chronic uremia. Kidney Int 1996; 49: 1428–1434.
18. Törnig J, Amann K, Ritz E et al. Arteriolar wall thickening, capillary rarefaction and interstitinal fibrosis in the heart of rats with renal failure: the effects of ramipril, nifedipine and moxonidine. J Am Soc Nephrol 1996; 7: 667–675.
19. Chertow GM, Normand SL, Silva LR et al. Survival after acute myocardial infarction in patients with end-stage renal disease: results from the cooperative cardiovascular project. Am J Kidney Dis 2000; 35: 1217–1220.
20. Pidgeon GB, Lynn KL, Bailey RR et al. Coronary angiography prior to renal tranplantation. Nephrology 1995; 1: 59–64.
21. Kaplan NM, Flynn JT. Kaplan’s clinical hypertension. 9th ed. Philadelphia: Lippincott Williams & Wilkins 2006.
22. Franklin SS, Polez VA, Wong ND et al. Prevalence, treatment, and control of hypertension in U.S. adults, 2001–2002, overall and individually among high cardiovascular disease risk groups. J Hypertens 2006; 24 (Suppl 6): S41.
23. Monhart V. Hypertenze u chronické renální insuficience. Medicína pro praxi 2009; 6: 73–76.
24. Mancia G, Laurent S, Agabiti-Rosei E et al. European Society of Hypertension. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens 2009; 27: 2121–2154.
25. Heerspink HJ, Ninomiya T, Zoungas S et al. Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: a systematic review and meta-analysis of randomised controlled trials. Lancet 2009; 373: 1009–1015.
26. Jacobsen P, Andersen S, Rossing K et al. Dual blockade of the renin-angiotensin system versus maxima recommended dose of ACE inhibitor in diabetic nephropathy. Kidney Int 2003; 63: 1874–1880.
27. Nakao N, Yoshimura A, Morita H et al. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003; 361: 117–124.
28. Parving H, Persson F, Lewis J et al. for the AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 2008; 358: 2433–2446.
29. Levin NW, Handelman GJ, Coresh J et al. Reverse epidemiology; confounding, and inaccurate term. Semin Dial 2007; 20: 586–592.
30. Kalantar-Zadeh K, Kilpatrick RD, McAllister CJ et al. Reverse epidemiology of hypertension and cardiovascular death in the hemodialysis population: the 58th annual fall conference and scientific sessions. Hypertension 2005; 45: 811–817.
31. Goldfarb-Rumyantzev AS, Baird BC, Leypoldt JK et al. The association between BP and mortality in patients on chronic peritoneal dialysis. Nephrol Dial Transplant 2005; 20: 1693–1701.
Labels
Diabetology Endocrinology Internal medicineArticle was published in
Internal Medicine
2011 Issue 7&8
Most read in this issue
- Haemodialysis – the current practice
- Anemia and chronic kidney failure
- Immunosuppressive therapy and its problems
- Aetiology and a clinical picture of chronic renal failure